货号:A172052
同义名:
AraG; ara-Guanosine
9-beta-Arabinosylguanine is an inducer of apoptosis, inhibitor of DNA synthesis, an antimetabolite, and antineoplastic.
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | 9-beta-D-arabinofuranosylguanine (ara-G) is a 2'-deoxyguanosine analogue which is 70-fold more inhibitory to the growth of T- than of B-lymphoblasts. It is less potent than ara-C but far more selective in its cytotoxic effect on T-cells. ara-G is not significantly degraded by purine nucleoside phosphorylase (EC 2.4.2.1) activity in T-lymphoblasts and is metabolized to 9-beta-D-arabinofuranosylguanine 5'-triphosphate. ara-G differs from 1-beta-D-arabinofuranosylcytosine in its selectivity for cultured T-lymphoblasts and may be of use as a chemotherapeutic or immunosuppressive agent[2]. AraG can cause hypomethylation of DNA and induce the expression of the fetal hemoglobin gamma gene and the ABCB1 gene[3]. Evidence of araG's ability to purge bone marrow of malignant tumor cells without causing significant toxicity to normal marrow derived hematopoietic progenitor cells was documented in experiments in which 75% of lethally irradiated mice transplanted with syngeneic bone marrow, contaminated with 6C3HED tumor cells and treated ex vivo with 100 microM araG for 18 hours, survived for > 250 to > 400 days[4]. |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT00866671 | - | Completed | - | Denmark ... 展开 >> GSK Investigational Site Aahur N, Denmark GSK Investigational Site Aalborg, Denmark, DK-9100 GSK Investigational Site Koebenhavn Oe, Denmark, 2100 GSK Investigational Site Odense C, Denmark France GSK Investigational Site Bordeaux cedex, France, 33076 GSK Investigational Site Lille Cedex, France, 59037 GSK Investigational Site Nantes Cedex 1, France, 44093 GSK Investigational Site Paris Cedex 10, France, 75475 GSK Investigational Site Paris cedex 12, France, 75571 GSK Investigational Site Paris Cedex 19, France, 75935 GSK Investigational Site Vandoeuvre-Les-Nancy, France, 54511 Germany GSK Investigational Site Essen, Nordrhein-Westfalen, Germany, 45122 GSK Investigational Site Hamburg, Germany, 20246 Israel GSK Investigational Site Beer-Sheva, Israel, 84101 GSK Investigational Site Haifa, Israel, 31096 GSK Investigational Site Petach-Tikva, Israel GSK Investigational Site Ramat Gan, Israel, 52621 Italy GSK Investigational Site Bologna, Emilia-Romagna, Italy, 40137 Netherlands GSK Investigational Site Rotterdam, Netherlands, 3015 GJ Poland GSK Investigational Site Bydgoszcz, Poland GSK Investigational Site Lublin, Poland, 20-093 GSK Investigational Site Warszawa, Poland, 00-576 GSK Investigational Site Warszawa, Poland, 02-781 GSK Investigational Site Wroclaw, Poland, 50-345 Russian Federation GSK Investigational Site Krasnodar, Russian Federation, 350007 GSK Investigational Site Moscow, Russian Federation, 117997 GSK Investigational Site Moscow, Russian Federation, 119049 Spain GSK Investigational Site Barcelona, Spain, 08035 GSK Investigational Site Boadilla del Monte (Madrid), Spain, 28660 GSK Investigational Site Madrid, Spain, 28009 GSK Investigational Site Madrid, Spain, 28047 收起 << | |
NCT03311672 | Non-small Cell Lung Cancer | Phase 2 | Recruiting | November 1, 2018 | United States, California ... 展开 >> University of California, San Francisco Recruiting San Francisco, California, United States, 94107 Contact: Dora Tao 415-514-6759 dora.tao@ucsf.edu 收起 << |
NCT03007719 | Bladder Cancer | Phase 2 | Recruiting | December 2018 | United States, California ... 展开 >> University of California, San Francisco Recruiting San Francisco, California, United States, 94158 Contact: Julie McCluggage, RN 877-827-3222 HDFCCC.CIP@ucsf.edu Contact: Lissa Gray, NP 877-827-3222 HDFCCC.CIP@ucsf.edu 收起 << |
计算器 | ||||
存储液制备 | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
3.53mL 0.71mL 0.35mL |
17.65mL 3.53mL 1.77mL |
35.31mL 7.06mL 3.53mL |
CAS号 | 38819-10-2 |
分子式 | C10H13N5O5 |
分子量 | 283.24 |
SMILES Code | O=C1NC(N)=NC2=C1N=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3O |
MDL No. | MFCD00065486 |
别名 | AraG; ara-Guanosine; Ara-G , ara-Guanosine, Guanine Arabinoside; NSC 76352; Guanine Arabinoside |
运输 | 蓝冰 |
InChI Key | NYHBQMYGNKIUIF-FJFJXFQQSA-N |
Pubchem ID | 135499520 |
存储条件 |
In solvent -20°C:3-6个月-80°C:12个月 Pure form Keep in dark place, sealed in dry, 2-8°C |
溶解方案 |
请根据您的动物给药指南选择适当的溶解方案。 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|